Dermatology and Therapy最新文献

{"title":"Correction: Three-Year Efficacy and Safety of Lebrikizumab in Patients with Moderate-to-Severe Atopic Dermatitis: A Long-Term Extension (ADjoin).","authors":"Emma Guttman-Yassky, Alan D Irvine, Melinda Gooderham, Stephan Weidinger, Lynda Spelman, Jonathan I Silverberg, Heidi Crane, Hany ElMaraghy, Louise DeLuca-Carter, Maria Lucia Buziqui Piruzeli, Georgia Martimianaki, Evangeline Pierce, Helena Agell, Diamant Thaçi","doi":"10.1007/s13555-026-01876-x","DOIUrl":"10.1007/s13555-026-01876-x","url":null,"abstract":"","PeriodicalId":11186,"journal":{"name":"Dermatology and Therapy","volume":" ","pages":"5263-5264"},"PeriodicalIF":4.6,"publicationDate":"2026-10-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC13650085/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148850078","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Factors Associated with Previous Aesthetic Procedures among Men: A Cross-Sectional Online Survey.","authors":"Andreza Cunha Moreira, Ana Claudia Carbone, Antony de Paula Barbosa, Murilo Fanchiotti Cerri, Anna Raphaella Autran Colaco, Gilberto Melo, Giancarlo De la Torre Canales","doi":"10.1007/s13555-026-01889-6","DOIUrl":"10.1007/s13555-026-01889-6","url":null,"abstract":"<p><strong>Introduction: </strong>The number of men undergoing aesthetic procedures has increased substantially worldwide, highlighting the need to understand the characteristics of those who undergo them. However, evidence focusing on male populations remains limited. This study aimed to describe the sociodemographic characteristics and FACE-Q scale patient-reported outcomes of men with and without previous aesthetic procedures, and to explore which characteristics were associated with having undergone them.</p><p><strong>Methods: </strong>This cross-sectional online survey included 231 men aged 18-65 years. Participants were allocated into two groups according to previous experience with aesthetic procedures: yes to aesthetic procedures (YAP; n = 93) and no to aesthetic procedures (NAP; n = 138). Sociodemographic variables and six independently functioning FACE-Q scales were collected: aging appraisal, appearance-related psychosocial distress, satisfaction with facial appearance, psychological function, social function, and satisfaction with lower face and jawline. Univariate between-group comparisons and exploratory multivariate analyses were performed.</p><p><strong>Results: </strong>Participants in the YAP group were more frequently from Brazil, aged ≥ 31 years, and in the higher-income group (p < 0.05). They reported lower Aging Appraisal scores, (trimmed mean difference -15.8; 95% CI -21.6 to -9.9), greater appearance-related psychosocial distress (+13.1; 95% CI 6.4-19.7), and lower satisfaction with facial appearance (- 8.6), psychological function (-8.6), and satisfaction with the lower face and jawline (-11.4). Multivariate analysis showed substantial overlap between groups (R²Y = 0.292; Q² = 0.256). In the exploratory logistic regression, Brazilian participants (OR 0.29; 95% CI 0.14-0.57), age ≥ 31 years (OR 2.35; 95% CI 1.08-5.13), and higher income (OR 2.90; 95% CI 1.27-6.61) were associated with previous aesthetic procedures, whereas no FACE-Q scale was independently associated with the outcome.</p><p><strong>Conclusions: </strong>Men undergoing previous aesthetic procedures did not demonstrate a clearly psychosocial profile compared with the general male population. However, age, country, and income, but not any FACE-Q, were independently associated with undergoing these procedures.</p>","PeriodicalId":11186,"journal":{"name":"Dermatology and Therapy","volume":" ","pages":"4975-4991"},"PeriodicalIF":4.6,"publicationDate":"2026-10-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC13650204/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148789432","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Patterns of Clinical Response in Rollover Adolescent Patients with Alopecia Areata Treated with Ritlecitinib in the Ongoing Long-Term, Open-Label, Phase 3 ALLEGRO-LT Study.","authors":"Ulrike Blume-Peytavi, Brittany Craiglow, Ilka Arun Netravali, Isabella Doche, Kazutoshi Harada, Dalia Wajsbrot, Gianluca Bonfanti, Rahmat Ishowo-Adejumo, Robert Wolk, Helen Tran","doi":"10.1007/s13555-026-01911-x","DOIUrl":"10.1007/s13555-026-01911-x","url":null,"abstract":"<p><strong>Introduction: </strong>Ritlecitinib, a JAK3/TEC family kinase inhibitor, demonstrated efficacy in adolescents with alopecia areata (AA) in the ALLEGRO phase 2b/3 study. The present study evaluated long-term Severity of Alopecia Tool (SALT) score response patterns in adolescents from ALLEGRO-2b/3 who rolled over into the open-label, phase 3 ALLEGRO-LT study.</p><p><strong>Methods: </strong>This post hoc analysis included adolescents aged 12-17 years with AA and ≥ 50% scalp hair loss who received ritlecitinib 50 mg daily, with or without a 4-week 200-mg loading dose. Individual SALT score trajectories from baseline to month 24 were used to categorize adolescents as early (SALT score ≤ 20 at week 24 and months 12 and 24), middle (SALT ≤ 20 at months 12 and 24), or late responders (SALT ≤ 20 at month 24) or partial responders (maintained 30% improvement), relapsers (achieved but did not maintain 30% improvement), or true non-responders (did not achieve 30% improvement). Baseline disease characteristics were assessed by SALT score ≤ 20 response status.</p><p><strong>Results: </strong>Among 57 adolescents, 42.1% had SALT score ≤ 20 response through month 24 (17.5% early, 17.5% middle, and 7.0% late responders). The remaining 57.9% did not achieve SALT score ≤ 20 response, with 15.8% partial responders, 21.1% relapsers, and 21.1% true non-responders. SALT score ≤ 20 responders had shorter AA episode duration, less frequent alopecia totalis/universalis, and were more frequently female versus non-responders.</p><p><strong>Conclusion: </strong>A large proportion of adolescents treated with ritlecitinib had an early, middle, or late SALT score ≤ 20 response pattern during 24 months of treatment. Responders (SALT score ≤ 20) had less extensive scalp hair loss and shorter AA episode duration at baseline, and a higher proportion of responders were female compared with non-responders (SALT score > 20). Infographic available for this article.</p><p><strong>Clinicaltrials: </strong></p><p><strong>Gov registration: </strong>NCT03732807 and NCT04006457.</p>","PeriodicalId":11186,"journal":{"name":"Dermatology and Therapy","volume":" ","pages":"5215-5227"},"PeriodicalIF":4.6,"publicationDate":"2026-10-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC13650212/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"149105259","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Rezpegaldesleukin and Regulatory T Cell Restoration in Immune-Mediated Skin Diseases.","authors":"João Domingues, Raj Chovatiya, Brett King, Tiago Torres","doi":"10.1007/s13555-026-01936-2","DOIUrl":"https://doi.org/10.1007/s13555-026-01936-2","url":null,"abstract":"<p><p>Inflammatory skin diseases such as atopic dermatitis (AD), psoriasis, and alopecia areata (AA) are characterized by immune dysregulation involving impaired regulatory T cell (T_reg) function and persistent activation of effector inflammatory pathways. Current targeted therapies largely suppress downstream inflammatory signaling rather than correcting upstream regulatory abnormalities. Rezpegaldesleukin (REZPEG; NKTR-358) is a first-in-class, T_reg-selective interleukin-2 (IL-2) receptor agonist engineered to preferentially expand cluster of differentiation 4 positive (CD4⁺) FOXP3⁺ T_regs while minimizing activation of conventional effector T cells and natural killer (NK) cells. This review summarizes the biological rationale, mechanism of action, and emerging clinical evidence supporting REZPEG across dermatologic indications, particularly AD and AA. In phase 1 and phase 1b studies, REZPEG induced selective and durable T_reg expansion, attenuation of inflammatory biomarkers, and clinical improvements in AD and psoriasis, including prolonged off-treatment responses. In the phase 2b REZOLVE-AD trial, all active dosing regimens significantly improved Eczema Area and Severity Index outcomes versus placebo, with responses maintained or further deepened through week 52 with monthly or quarterly maintenance dosing. In severe AA, the phase 2b REZOLVE-AA trial did not meet its primary endpoint: mean Severity of Alopecia Tool (SALT) reductions at week 36 were 28.2% and 30.3% with REZPEG 24 and 18 µg/kg, respectively, versus 11.2% with placebo (p = 0.186 and p = 0.121). A supportive sensitivity analysis excluding four participants with major eligibility violations reached statistical significance, while hypothesis-generating extension data suggested further hair regrowth through week 52. Across completed studies, REZPEG has demonstrated a favorable tolerability profile, predominantly characterized by mild injection-site reactions, without major safety signals. Collectively, these findings support selective T_reg expansion as a mechanistically novel therapeutic strategy in immune-mediated skin disease, while further controlled studies are needed to define REZPEG's long-term efficacy and therapeutic positioning.</p>","PeriodicalId":11186,"journal":{"name":"Dermatology and Therapy","volume":" ","pages":""},"PeriodicalIF":4.6,"publicationDate":"2026-10-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"149105285","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Real-World Treatment Patterns, Healthcare Resource Utilisation, and Costs in Biologic-Naïve Patients with Moderate-to-Severe Psoriasis Treated with Biologics in France.","authors":"Thierry Passeron, Richard Ta, Véronique Hospital, Keith A Betts, Maryaline Catillon, Calvin Plays, Denis Jullien","doi":"10.1007/s13555-026-01887-8","DOIUrl":"10.1007/s13555-026-01887-8","url":null,"abstract":"<p><strong>Introduction: </strong>Real-world evidence investigating treatment patterns and associated economic outcomes in patients with psoriasis (PsO) are lacking. This study evaluated treatment patterns, healthcare resource utilisation (HCRU), and costs in biologic-naïve patients with moderate-to-severe PsO initiating biologics in France.</p><p><strong>Methods: </strong>Biologic-naïve adults with moderate-to-severe PsO initiating an anti-tumour necrosis factor (TNFα) or anti-interleukin (IL) biologic were identified from the Système National des Données de Santé. Switching and dose escalation rates, calculated using Kaplan-Meier analyses, were assessed over 42 months of follow-up. HCRU and costs were assessed during the 12 months following initiation. Comparisons between switchers/non-switchers and dose escalators/non-dose escalators were conducted using Wilcoxon rank sum, chi-square, and Fisher exact tests.</p><p><strong>Results: </strong>Overall, 20,995 biologic-naïve adult patients initiating a biologic were included in the analysis. At 42 months, switch rates and dose escalation rates were lowest for patients initiating anti-IL-23 agents and highest for anti-TNFα agents. Specifically, the lowest rate of switching (15.0%) and dose escalation (9.0%) were observed for patients treated with the anti-IL-23 agent risankizumab. The mean number of total healthcare visits at 12 months was significantly (p < 0.001) higher for treatment switchers versus non-switchers (48.8 vs 39.0) and dose escalators versus non-dose escalators (47.4 vs 39.9). Furthermore, switchers had significantly (p < 0.001) higher mean medical (€3435 vs €2578), inpatient (€1126 vs €826), outpatient (€1751 vs €1331), and pharmacy (€13,105 vs €10,589) costs versus non-switchers. Similar trends were observed for dose escalators versus non-dose escalators (€3453 vs €2638; €965 vs €870; €1682 vs €1371; and €13,736 vs €10,683, respectively, p < 0.001).</p><p><strong>Conclusion: </strong>Anti-IL-23 agents demonstrated the lowest rates of switching and dose escalation over 42 months, whilst anti-TNFα agents had the highest rates. More specifically, the lowest rates were observed for patients treated with risankizumab. Overall, higher rates of switching or dose escalation corresponded with higher HCRU and costs.</p>","PeriodicalId":11186,"journal":{"name":"Dermatology and Therapy","volume":" ","pages":"5013-5035"},"PeriodicalIF":4.6,"publicationDate":"2026-10-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC13650109/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148789414","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Bimekizumab as an Effective Treatment in Darier Disease: Clinical Outcomes of a Single-Center Retrospective Analysis of Patients Treated with Biologics.","authors":"David L Ranzinger, Paul Schmidle, Matthias Seifert, Sophia Wasserer, Kristin Technau-Hafsi, Cristina Has, Kilian Eyerich, Anna C Pilz","doi":"10.1007/s13555-026-01890-z","DOIUrl":"10.1007/s13555-026-01890-z","url":null,"abstract":"<p><strong>Introduction: </strong>Darier disease (DD) is a rare autosomal dominant genodermatosis with limited systemic therapeutic options. Retinoids are the gold standard therapy, but long-term application is frequently limited by adverse events. Case reports suggest that biologicals approved for psoriasis vulgaris or atopic dermatitis may be beneficial in DD.</p><p><strong>Methods: </strong>In this retrospective study, patients with DD who presented to the Department of Dermatology and Venerology, University Hospital Freiburg, between 2019 and 2024 were identified, and clinical efficacy, patient-reported outcomes, and histological features were analyzed in the patients treated with biologic agents in routine care.</p><p><strong>Results: </strong>In total, 15 patients (female: 11, male: 4) with a mean age of 48.20 ± 9.16 years were treated with biologic agents. The three patients who received the type 2 inhibitors dupilumab or lebrikizumab worsened or remained unchanged and discontinued therapy by week 12. Patients treated with the interleukin-17A/F inhibitor bimekizumab showed reduction of the Investigator Global Assessment score and body surface area from a mean of 3.58 ± 0.56 at baseline to 1.80 ± 0.82 at week 24 (p < 0.001) and from 32.00 ± 19.17% to 13.60 ± 9.05% (week 24; p < 0.001), respectively. The Dermatology Life Quality Index score decreased from 18.45 ± 9.87 to 4.78 ± 6.12 (week 24; p < 0.001). Additionally, on histopathology, the total numbers of dyskeratoses showed a trend towards reduction (31.17 ± 10.19 at baseline to 13.67 ± 13.25 at week 12; p = 0.062) with a decrease in the number of grains (10.50 ± 6.77 to 3.33 ± 3.88; p = 0.031).</p><p><strong>Conclusions: </strong>In summary, these real-world data indicate that bimekizumab may be a beneficial and relatively safe treatment option in DD.</p>","PeriodicalId":11186,"journal":{"name":"Dermatology and Therapy","volume":" ","pages":"5133-5148"},"PeriodicalIF":4.6,"publicationDate":"2026-10-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC13650225/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148954960","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"EP262, an MRGPRX2 Antagonist for the Treatment of Atopic Dermatitis: Results From the Phase 2 Randomized EASE Study.","authors":"Shirley Dehn, Daniel Cooper, Christian Weyer, Beatrice Ferguson, Swetha Srinivasan, Etienne Saint-Cyr Proulx, Robert Bissonnette","doi":"10.1007/s13555-026-01883-y","DOIUrl":"10.1007/s13555-026-01883-y","url":null,"abstract":"<p><strong>Introduction: </strong>Mas-related G protein-coupled receptor X2 (MRGPRX2) levels are elevated in patients with atopic dermatitis (AD). EP262, a small-molecule MRGPRX2 receptor antagonist, significantly diminished AD development in humanized mouse models of AD. In the EASE study, the safety, tolerability, and pharmacodynamics of EP262 were compared with placebo in patients with AD.</p><p><strong>Methods: </strong>Patients aged 18-80 years with AD, 3%-20% affected body surface area, and validated Investigator's Global Assessment for AD (vIGA-AD) score ≥ 3 were randomized 2:1 to receive 150 mg EP262 or placebo once daily for 6 weeks. The primary endpoint was safety and tolerability. The secondary endpoint was change from baseline to Week 6 in gene expression signature and skin histology. Exploratory efficacy endpoints included Eczema Area and Severity Index (EASI), vIGA-AD, and Peak Pruritus Numerical Rating Scale (PP-NRS).</p><p><strong>Results: </strong>Of 32 randomized patients (median [range] age, 41.0 [18-70] years), treatment-emergent adverse events (TEAEs) were reported in 19.0% of patients who received EP262 and 63.6% who received placebo, with none considered treatment-related. No grade ≥ 3 or serious TEAEs were observed, and no TEAEs led to dose interruptions or treatment discontinuations. No genes were differentially expressed between baseline lesional or nonlesional samples and Week 6 lesional samples. Differences in epidermal thickness were not meaningful between groups following treatment. No improvement was observed at Week 6 between EP262 and placebo in EASI (mean percentage change from baseline, - 14.9% vs - 40.7%), vIGA-AD (patients scoring 0/1 with  ≥ 2-point improvement from baseline, 21.1% vs 27.3%), or PP-NRS scores (mean percentage change from baseline, - 26.7% vs - 25.1%).</p><p><strong>Conclusions: </strong>EP262 was well tolerated in patients with AD. No meaningful differences were observed in gene expression, skin thickness, or efficacy measures in patients who received EP262 versus placebo.</p><p><strong>Trial registration: </strong>Clinicaltrials.gov identifier, NCT06144424 (registered on November 16, 2023).</p>","PeriodicalId":11186,"journal":{"name":"Dermatology and Therapy","volume":" ","pages":"5245-5255"},"PeriodicalIF":4.6,"publicationDate":"2026-10-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC13650203/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148789375","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Prophylactic Medium-Class Topical Steroids are Associated with a Lower Incidence of Capecitabine-Induced Hand-Foot Syndrome in Patients with Colorectal Cancer.","authors":"Yohei Iimura, Yuka Ahiko, Satoko Monma, Naoki Sakuyama, Susumu Aikou, Dai Shida, Seiichiro Kuroda","doi":"10.1007/s13555-026-01898-5","DOIUrl":"10.1007/s13555-026-01898-5","url":null,"abstract":"<p><strong>Introduction: </strong>There is limited clinical research evaluating the role of topical corticosteroids in preventing hand-foot syndrome (HFS) caused by capecitabine. Although the precise cause of HFS remains unclear, inflammatory mechanisms are thought to contribute to its development. This study investigated whether prophylactic use of a medium-class topical corticosteroid was associated with a lower incidence of capecitabine-related HFS in patients with colorectal cancer.</p><p><strong>Methods: </strong>We retrospectively assessed 78 patients prescribed medium-class topical steroids as a preventive against HFS associated with capecitabine and 32 topical steroid-free patients undergoing capecitabine-based chemotherapy. We evaluated the incidence of each grade of HFS during chemotherapy.</p><p><strong>Results: </strong>Between January 2022 and March 2025, 110 patients were enrolled in the study. Grade ≥ 2 HFS occurred in 23.1% of patients in the medium-class topical steroid group and 50.0% of patients in the topical steroid-free group (OR, 0.30; 95% CI 0.13-0.72; P = 0.012, Fisher's exact test). The incidence of other capecitabine-related adverse events did not differ significantly between the groups.</p><p><strong>Conclusion: </strong>Our findings suggest that prophylactic use of medium-class topical steroids was associated with a lower incidence of capecitabine-induced hand-foot syndrome. Prospective randomized studies are warranted to confirm these findings.</p>","PeriodicalId":11186,"journal":{"name":"Dermatology and Therapy","volume":" ","pages":"5085-5097"},"PeriodicalIF":4.6,"publicationDate":"2026-10-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC13650209/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148849606","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Therapeutic Journey Among Patients with Acne Treated with Isotretinoin.","authors":"John S Barbieri, Jerry Tan, Megha Tollefson, Firas Dabbous, Divya Shridharmurthy, Samuel Huse, Sarah Naeger, Esteban Puentes-Rosas","doi":"10.1007/s13555-026-01894-9","DOIUrl":"10.1007/s13555-026-01894-9","url":null,"abstract":"<p><strong>Introduction: </strong>Although isotretinoin is approved for severe recalcitrant nodular acne, it is broadly used among patients with acne in clinical practice. The objective of this study was to characterize the profile and therapeutic journey of patients with acne treated with isotretinoin.</p><p><strong>Methods: </strong>Using the MarketScan® Commercial Claims and Encounters Database, we identified patients diagnosed with acne who received isotretinoin before 30 June 2023. Outcomes included: time to isotretinoin discontinuation, antibiotic initiation after isotretinoin discontinuation, isotretinoin restart, and acne treatment reinitiation. Treatment courses prior to isotretinoin initiation were also assessed.</p><p><strong>Results: </strong>A total of 71,340 patients were included. Overall, 28.4% initiated isotretinoin without prior acne treatment, 48.3% had ≥ 1 and 23.3% had ≥ 2. Adolescents were more likely to have multiple prior acne treatments compared with adults, who more frequently started isotretinoin without prior acne therapy (34.0% versus 25.7%). The median time to isotretinoin discontinuation was 5.97 months. At 12 months following isotretinoin discontinuation, 5.4% of patients restarted isotretinoin and 12.1% initiated antibiotic therapy.</p><p><strong>Conclusions: </strong>Our findings highlight the substantial burden of acne requiring isotretinoin and underscore the need for tailored treatment approaches that account for differences in age, sex, and real-world treatment patterns.</p>","PeriodicalId":11186,"journal":{"name":"Dermatology and Therapy","volume":" ","pages":"5149-5159"},"PeriodicalIF":4.6,"publicationDate":"2026-10-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC13650086/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148900216","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Real-World Use of Adjuvant Nivolumab for Resected Stage III-IV Melanoma: 2-Year Analysis of AdjuMel.","authors":"Stéphane Dalle, Philippe Saiag, Céleste Lebbé, Jean-Jacques Grob, Brigitte Dréno, Sophie Dalac, Bernard Asselain, François Skowron, Sophie Darras, Nicolas Jovenin, Gaëlle Quereux, Amir Khammari, Capucine Rieuf, Florence Brellier, Laurent Mortier","doi":"10.1007/s13555-026-01853-4","DOIUrl":"10.1007/s13555-026-01853-4","url":null,"abstract":"<p><strong>Introduction: </strong>Following the positive findings of the phase 3 CheckMate 238 trial, adjuvant nivolumab has become a standard therapy in patients with completely resected stage III-IV melanoma. The prospective, ongoing AdjuMel study is evaluating the real-world use, effectiveness, and safety of adjuvant nivolumab in patients with resected melanoma in France. Here we report 2-year results from the third interim analysis of AdjuMel.</p><p><strong>Methods: </strong>This observational, prospective study is evaluating data from patients with resected stage III-IV melanoma treated with adjuvant nivolumab in France. Study outcomes include effectiveness, safety, and treatment patterns of anti-programmed cell death-1 (PD-1, nivolumab) under routine clinical practice in the adjuvant setting. The primary endpoint was relapse-free survival (RFS). This third interim analysis (data cut-off: 3 November 2023) included patients with ≥ 1 follow-up visit, using data collected up to the 24-month visit.</p><p><strong>Results: </strong>Overall, 343 patients (median [range] age 65 [27-95] years; 57.7% male; 41.7% BRAF-mutation positive) were evaluable in this interim analysis, with a median (range) follow-up of 23.4 (2.1-27.3) months. At treatment initiation, 86.8% and 13.2% of patients had stage III and IV disease, respectively. The 2-year RFS rate was 52.8% (95% confidence interval 47.0-58.2). The risk of recurrence or death was lower in patients with stage IIIA disease versus IIIB-D (hazard ratio [HR] 0.43) and in those aged < 75 versus ≥ 75 years (HR 0.56), and higher in patients with versus without tumor ulceration (HR 1.99). The safety profile of adjuvant nivolumab was consistent with that reported in CheckMate 238, and patient quality of life did not appear to be adversely affected.</p><p><strong>Conclusions: </strong>These real-world data are in line with those reported in randomized clinical trials, despite the broader inclusion criteria of the study population.</p><p><strong>Trial registration: </strong>ClinicalTrials.gov identifier: NCT04550247.</p>","PeriodicalId":11186,"journal":{"name":"Dermatology and Therapy","volume":" ","pages":"5117-5132"},"PeriodicalIF":4.6,"publicationDate":"2026-10-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC13650221/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148857164","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}